Selective Akt3 Modulation for Immune Response Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular mechanisms of Akt isoform-specific roles in Treg development and function are not fully understood, and existing methods fail to effectively modulate Akt3 activity to regulate immune responses in subjects with autoimmune diseases or cancers.
Innovation Solution
Compounds and compositions are developed to selectively inhibit or activate Akt3 activity, modulating immune responses by increasing or decreasing immune suppressive or stimulating responses, thereby affecting Treg activity and cytokine secretion in subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are developed to selectively inhibit or activate Akt3 activity, then immune responses can be modulated to treat cancers and autoimmune diseases, but the molecular mechanisms of Akt isoform-specific roles in Treg development and function remain not fully understood
Solution Approach 1:
The patent segments the Akt signaling pathway by developing compounds that selectively target Akt3 isoform specifically, rather than acting on all Akt isoforms (Akt1, Akt2, Akt3). This selective segmentation allows modulation of immune responses through Akt3-specific inhibition or activation, enabling therapeutic applications while the complex molecular mechanisms of isoform-specific roles continue to be investigated.
2Adaptability or versatility
If existing methods are used to modulate immune responses, then general immune modulation is achieved, but effective modulation of Akt3 activity to regulate immune responses in subjects with autoimmune diseases or cancers is not achieved
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (e.g., Formula I with particular substituent patterns at R1, R2, R3 positions) that confer selective affinity for Akt3 isoform. This localized molecular design enables precise targeting of Akt3 activity while sparing other Akt isoforms, achieving the needed precision for effective immune response modulation in autoimmune diseases and cancers.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying chemical parameters (substituents R1-R6, ring structures A-D) in the compound formulas to optimize selectivity for Akt3. By adjusting these molecular parameters, the compounds achieve differential binding affinity and inhibitory/activating potency specifically for Akt3, enabling precise modulation of its activity in immune cell function.
Data Source
AI summary
Compounds and compositions for selectively modulating Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.